Abstract
Adoptive T cell therapies can produce objective clinical responses in patients with hematologic and solid malignancies. Genetic manipulation of T lymphocytes has been proposed as a means of increasing the potency and range of this anti-tumor activity. We now review how coupling expression of transgenic receptors with countermeasures against potent tumor immune evasion strategies is proving highly effective in pre-clinical models and describe how these approaches are being evaluated in human subjects.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 396-408 |
| Number of pages | 13 |
| Journal | Current Gene Therapy |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2009 |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Drug Discovery
- Genetics(clinical)
Fingerprint
Dive into the research topics of 'Immunotherapy of human cancers using gene modified T lymphocytes'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS